Related Experiment Video

Updated: Jun 11, 2026

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Vaccines as monotherapy and in combination therapy for prostate cancer

Julia Rotow1, Sofia R Gameiro, Ravi A Madan

  • 1Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.

Clinical and Translational Science
|July 2, 2010
PubMed

Insights

Novel cancer vaccines offer a promising new approach for treating advanced prostate cancer. This research explores innovative vaccine strategies for metastatic castration-resistant prostate cancer in late-stage clinical trials.

Area of Science:

  • Oncology
  • Immunology
  • Cancer Therapeutics

Background:

  • Prostate cancer is a leading cause of cancer death in men.
  • Current chemotherapy for metastatic castration-resistant prostate cancer (mCRPC) offers limited survival benefits.
  • There is a critical need for alternative and improved treatment strategies for mCRPC.

Purpose of the Study:

  • To review novel therapeutic cancer vaccine strategies for prostate cancer.
  • To focus on vaccine approaches that have progressed to late-stage clinical studies for mCRPC.
  • To highlight advancements in targeted immunotherapy for advanced prostate cancer.

Main Methods:

  • Review of scientific literature and clinical trial data.
  • Focus on vaccine strategies translated into late-stage clinical development.
  • Analysis of therapeutic approaches for castration-resistant prostate cancer.

Main Results:

  • Therapeutic cancer vaccines represent a novel targeted approach for prostate cancer.
  • Several vaccine strategies are under investigation for various stages of prostate cancer.
  • The article specifically examines vaccines that have reached late-stage clinical trials for mCRPC.

Conclusions:

  • Therapeutic cancer vaccines show potential as an alternative or supplementary treatment for mCRPC.
  • Advancements in vaccine technology are driving new treatment options for advanced prostate cancer.
  • Late-stage clinical studies are crucial for validating the efficacy of these novel vaccine strategies.

More Related Videos

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Related Concept Videos

Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...